{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:17:01Z","timestamp":1773249421390,"version":"3.50.1"},"reference-count":60,"publisher":"China Science Publishing & Media Ltd.","issue":"2","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.3724\/abbs.2024104","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T04:43:57Z","timestamp":1718081037000},"page":"209-222","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Using protein turnover assay to explore the drug mechanism of Carfilzomib"],"prefix":"10.3724","volume":"57","author":[{"given":"Yonghui","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1745-7270.2008.00441.x","volume":"40","author":"Gao X","year":"2008","unstructured":"Gao X, Hu H. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin, 2008, 40: 612-618.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/procel\/pwad045","volume":"15","author":"Sheng X","year":"2023","unstructured":"Sheng X, Xia Z, Yang H, Hu R. The ubiquitin codes in cellular stress responses. Protein Cell, 2023, 15: 157-190.","journal-title":"Protein Cell"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1002\/anie.201201616","volume":"51","author":"Huber EM","year":"2012","unstructured":"Huber EM, Groll M. Inhibitors for the immuno\u2010 and constitutive proteasome: current and future trends in drug development. Angew Chem Int Ed, 2012, 51: 8708-8720.","journal-title":"Angew Chem Int Ed"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/cr.2014.122","volume":"24","author":"Yu T","year":"2014","unstructured":"Yu T, Tao Y, Yang M, Chen P, Gao X, Zhang Y, Zhang T. Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis. Cell Res, 2014, 24: 1214-1230.","journal-title":"Cell Res"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"33713","DOI":"10.1074\/jbc.R109.018481","volume":"284","author":"Navon A","year":"2009","unstructured":"Navon A, Ciechanover A. The 26 s proteasome: from basic mechanisms to drug targeting. J Biol Chem, 2009, 284: 33713-33718.","journal-title":"J Biol Chem"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.2174\/1381612811319220018","volume":"19","author":"Miller Z","year":"2013","unstructured":"Miller Z, Ao L, Bo Kim K, Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des, 2013, 19: 4140-4151.","journal-title":"Curr Pharm Des"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2020.12.020","volume":"21","author":"Kambhampati S","year":"2021","unstructured":"Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A. Carfilzomib in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin lymphoma: a phase I trial. Clin Lymphoma Myeloma Leukemia, 2021, 21: 139-146.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"Raab MS","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet, 2009, 374: 324-339.","journal-title":"Lancet"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom13111629","volume":"13","author":"Sharma NS","year":"2023","unstructured":"Sharma NS, Choudhary B. Good cop, bad cop: profiling the immune landscape in multiple myeloma. Biomolecules, 2023, 13:","journal-title":"Biomolecules"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.1141448","volume":"319","author":"Balch WE","year":"2008","unstructured":"Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science, 2008, 319: 916-919.","journal-title":"Science"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/cancers12123764","volume":"12","author":"Wirth M","year":"2020","unstructured":"Wirth M, Schick M, Keller U, Kr\u00f6nke J. Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy. Cancers, 2020, 12:","journal-title":"Cancers"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"Richardson PG","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 2005, 352: 2487-2498.","journal-title":"N Engl J Med"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"Dimopoulos M","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, Miguel JS. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 2007, 357: 2123-2132.","journal-title":"N Engl J Med"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"Weber DM","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D. Lenalidomide plus dexamethasone for relapsed multiple myeloma in north America. N Engl J Med, 2007, 357: 2133-2142.","journal-title":"N Engl J Med"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"Richardson PG","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 2006, 24: 3113-3120.","journal-title":"J Clin Oncol"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"Kortuem KM","year":"2013","unstructured":"Kortuem KM, Stewart AK. Carfilzomib. Blood, 2013, 121: 893-897.","journal-title":"Blood"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"Richardson PG","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003, 348: 2609-2617.","journal-title":"N Engl J Med"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","volume":"96","author":"Meng L","year":"1999","unstructured":"Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA, 1999, 96: 10403-10408.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","volume":"124","author":"Bringhen S","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood, 2014, 124: 63-69.","journal-title":"Blood"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/leu.2014.27","volume":"28","author":"Berenson JR","year":"2014","unstructured":"Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia, 2014, 28: 1529-1536.","journal-title":"Leukemia"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","volume":"122","author":"Wang M","year":"2013","unstructured":"Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, 122: 3122-3128.","journal-title":"Blood"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"Jakubowiak AJ","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, 120: 1801-1809.","journal-title":"Blood"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1182\/blood.V118.21.1263.1263","volume":"118","author":"Papadopoulos KP","year":"2011","unstructured":"Papadopoulos KP, Lee P, Singhal S, Holahan JR, Vesole DH, Rosen ST, Kunkel L. What is the role of red blood cell transfusion threshold on number of transfusions in pediatric patients after hematopoietic stem cell transplant?. Blood, 2011, 118:","journal-title":"Blood"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2023.2300051","volume":"65","author":"Weisel K","year":"2024","unstructured":"Weisel K, Dimopoulos MA, Beksac M, Leleu X, Richter J, Heeg B, Patel S. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed\/refractory multiple myeloma: an indirect treatment comparison. Leukemia Lymphoma, 2024, 65: 1-12.","journal-title":"Leukemia Lymphoma"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.1160489","volume":"322","author":"Yen HCS","year":"2008","unstructured":"Yen HCS, Xu Q, Chou DM, Zhao Z, Elledge SJ. Global protein stability profiling in mammalian cells. Science, 2008, 322: 918-923.","journal-title":"Science"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1002\/anie.200501023","volume":"44","author":"Walsh CT","year":"2005","unstructured":"Walsh CT, Garneau\u2010Tsodikova S, Gatto Jr. GJ. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed, 2005, 44: 7342-7372.","journal-title":"Angew Chem Int Ed"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/pro.666","volume":"20","author":"Varshavsky A","year":"2011","unstructured":"Varshavsky A. The N\u2010end rule pathway and regulation by proteolysis. Protein Sci, 2011, 20: 1298-1345.","journal-title":"Protein Sci"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"Meister S","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res, 2007, 67: 1783-1792.","journal-title":"Cancer Res"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","volume":"66","author":"Bazzaro M","year":"2006","unstructured":"Bazzaro M, Lee MK, Zoso A, Stirling WLH, Santillan A, Shih IM, Roden RBS. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor\u2013induced apoptosis. Cancer Res, 2006, 66: 3754-3763.","journal-title":"Cancer Res"},{"key":"CITATION30","unstructured":"Hideshima T, Richardson PG, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma (MM) cells. Blood 2000, 96: 461a-461a."},{"key":"CITATION31","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61: 3071-3076."},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"Kuhn DJ","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110: 3281-3290.","journal-title":"Blood"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/jnci\/djr160","volume":"103","author":"Ruschak AM","year":"2011","unstructured":"Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. JNCI-J Natl Cancer Institute, 2011, 103: 1007-1017.","journal-title":"JNCI-J Natl Cancer Institute"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"Dennis Jr G","year":"2003","unstructured":"Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol, 2003, 4:","journal-title":"Genome Biol"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"Huang DW","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 2009, 37: 1-13.","journal-title":"Nucleic Acids Res"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"Huang DW","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009, 4: 44-57.","journal-title":"Nat Protoc"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/nar\/gkg115","volume":"31","author":"Thomas PD","year":"2003","unstructured":"Thomas PD. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res, 2003, 31: 334-341.","journal-title":"Nucleic Acids Res"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"D684","DOI":"10.1093\/nar\/gkm795","volume":"36","author":"Kuhn M","year":"2008","unstructured":"Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res, 2008, 36: D684-D688.","journal-title":"Nucleic Acids Res"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"Shannon P","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13: 2498-2504.","journal-title":"Genome Res"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/2045-9912.273957","volume":"9","author":"Goshi E","year":"2019","unstructured":"Goshi E, Zhou G, He Q. Nitric oxide detection methods in vitro and in vivo. Med Gas Res, 2019, 9: 192-207.","journal-title":"Med Gas Res"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"Chou TC","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res, 2010, 70: 440-446.","journal-title":"Cancer Res"},{"key":"CITATION42","unstructured":"Hou J, Lin FY, Zhang B, Zhang LZ, Ding SQ. Establishment and biological characteristics of human multiple myeloma cell line CZ-1. Chinese Med J-Peking 2004, 117: 115-119."},{"key":"CITATION43","doi-asserted-by":"crossref","unstructured":"Varshavsky A. Ubiquitin fusion technique and related methods. Method Enzymol 2005, 399: 777-799.","DOI":"10.1016\/S0076-6879(05)99051-4"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"D401","DOI":"10.1093\/nar\/gkt1207","volume":"42","author":"Kuhn M","year":"2014","unstructured":"Kuhn M, Szklarczyk D, Pletscher-Frankild S, Blicher TH, von Mering C, Jensen LJ, Bork P. STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res, 2014, 42: D401-D407.","journal-title":"Nucleic Acids Res"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"Szklarczyk D","year":"2011","unstructured":"Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res, 2011, 39: D561-D568.","journal-title":"Nucleic Acids Res"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"Hideshima T","year":"2003","unstructured":"Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101: 1530-1534.","journal-title":"Blood"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"114907","DOI":"10.1016\/j.biopha.2023.114907","volume":"164","author":"Dabour MS","year":"2023","unstructured":"Dabour MS, Abdelgawad IY, Grant MKO, El-Sawaf ES, Zordoky BN. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomed Pharmacother, 2023, 164:","journal-title":"Biomed Pharmacother"},{"key":"CITATION48","doi-asserted-by":"crossref","unstructured":"von Mikecz A, Chen M, Rockel T, Scharf A. The nuclear ubiquitin-proteasome system: visualization of proteasomes, protein aggregates, and proteolysis in the cell nucleus. Methods Mol Biol 2008, 463: 191-202.","DOI":"10.1007\/978-1-59745-406-3_14"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"Engelman JA","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006, 7: 606-619.","journal-title":"Nat Rev Genet"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1097-2765(05)00089-4","volume":"6","author":"Walker EH","year":"2000","unstructured":"Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell, 2000, 6: 909-919.","journal-title":"Mol Cell"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20061489","volume":"404","author":"Gharbi SI","year":"2007","unstructured":"Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J, 2007, 404: 15-21.","journal-title":"Biochem J"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1042\/BJ20090489","volume":"421","author":"Garcia-Martinez JM","year":"2009","unstructured":"Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J, 2009, 421: 29-42.","journal-title":"Biochem J"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc3262","volume":"12","author":"White E","year":"2012","unstructured":"White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer, 2012, 12: 401-410.","journal-title":"Nat Rev Cancer"},{"key":"CITATION54","doi-asserted-by":"crossref","unstructured":"Choi AM, Ryter SW, Levine B. Autophagy in human health and disease.  N Engl J Med 2013, 368: 1845\u20131846.","DOI":"10.1056\/NEJMc1303158"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molcel.2011.02.009","volume":"42","author":"Elgendy M","year":"2011","unstructured":"Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic ras-induced expression of noxa and beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell, 2011, 42: 23-35.","journal-title":"Mol Cell"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40779-022-00392-1","volume":"9","author":"Wang CC","year":"2022","unstructured":"Wang CC, Peng H, Wang Z, Yang J, Hu RG, Li CY, Geng WJ. TRIM72-mediated degradation of the short form of p62\/SQSTM1 rheostatically controls selective autophagy in human cells. Military Med Res, 2022, 9:","journal-title":"Military Med Res"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccr.2014.05.015","volume":"26","author":"Liu Z","year":"2014","unstructured":"Liu Z, Chen P, Gao H, Gu Y, Yang J, Peng H, Xu X. Ubiquitylation of autophagy receptor optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell, 2014, 26: 106-120.","journal-title":"Cancer Cell"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2013.04.001","volume":"23","author":"Carroll RG","year":"2013","unstructured":"Carroll RG, Martin SJ. Autophagy in multiple myeloma: what makes you stronger can also kill you. Cancer Cell, 2013, 23: 425-426.","journal-title":"Cancer Cell"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2013.02.017","volume":"23","author":"Lamy L","year":"2013","unstructured":"Lamy L, Ngo VN, Emre NCT, Shaffer Iii AL, Yang Y, Tian E, Nair V. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell, 2013, 23: 435-449.","journal-title":"Cancer Cell"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"Oerlemans R","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL. Molecular basis of bortezomib resistance: proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112: 2489-2499.","journal-title":"Blood"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/06E667E126EA4781A20FD5287A63C461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2024104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/06E667E126EA4781A20FD5287A63C461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T01:44:54Z","timestamp":1757641494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2024104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,8]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2024104","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}